VYGR - Voyager Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue7,61910,13514,22017,334
Cost of Revenue64,90562,26042,24927,679
Gross Profit-57,286-52,125-28,029-10,345
Operating Expenses
Research Development----
Selling General and Administrative33,80919,73813,2709,909
Non Recurring----
Total Operating Expenses98,71481,99855,51937,588
Operating Income or Loss-91,095-71,863-41,299-20,254
Income from Continuing Operations
Total Other Income/Expenses Net2,6271,1651,158-9,418
Earnings Before Interest and Taxes-91,095-71,863-41,299-20,254
Interest Expense----
Income Before Tax-88,468-70,698-40,141-29,672
Income Tax Expense-180-52-
Minority Interest----
Net Income From Continuing Ops-88,288-70,698-40,193-29,672
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-88,288-70,698-40,193-29,672
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-88,288-70,698-40,193-38,290